{"doi":"10.1016/j.ejca.2022.06.024","title":"Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study","abstract":null,"journal":"European Journal of Cancer","year":2022,"id":598286,"datarank":0.4493598410330987,"base_score":2.995732273553991,"endowment":2.995732273553991,"self_citation_contribution":0.4493598410330987,"citation_network_contribution":0.0,"self_endowment_contribution":0.4493598410330987,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":19,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":105144,"name":"Daniel Castellano","orcid":"0000-0002-9106-0687","position":1,"is_corresponding":false},{"id":1532963,"name":"Jerome Alexandre","orcid":null,"position":2,"is_corresponding":false},{"id":629764,"name":"Sant P. Chawla","orcid":"0000-0002-9522-6744","position":3,"is_corresponding":false},{"id":940091,"name":"Cristian Fernández","orcid":"0000-0003-0333-4690","position":4,"is_corresponding":false},{"id":940596,"name":"Carmen Kahatt","orcid":null,"position":5,"is_corresponding":false},{"id":940092,"name":"Vicente Alfaro","orcid":"0000-0002-0150-2390","position":6,"is_corresponding":false},{"id":940597,"name":"Mariano Siguero","orcid":null,"position":7,"is_corresponding":false},{"id":940598,"name":"Ali Zeaiter","orcid":null,"position":8,"is_corresponding":false},{"id":1288207,"name":"Victor Moreno","orcid":null,"position":9,"is_corresponding":false},{"id":1269720,"name":"Enrique Sanz‐García","orcid":"0000-0002-3119-3832","position":10,"is_corresponding":false},{"id":545860,"name":"Ahmad Awada","orcid":"0000-0001-7412-9163","position":11,"is_corresponding":false},{"id":1532975,"name":"Ana Santaballa","orcid":null,"position":12,"is_corresponding":false},{"id":226642,"name":"Vivek Subbiah","orcid":"0000-0002-6064-6837","position":13,"is_corresponding":false},{"id":1419708,"name":"Federico Longo-Muñoz","orcid":"0000-0003-0902-2188","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study","abstract":"BACKGROUND: Patients with neuroendocrine tumours (NETs) need alternative therapies after failure of first-line therapy. PATIENTS AND METHODS: as a 1-h intravenous infusion every 3 weeks in 32 NETs patients treated in the second- or third-line setting. The primary efficacy endpoint was overall response rate (ORR) according to RECIST v1.1 assessed by the investigators. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS) and safety. RESULTS: Two of 31 evaluable patients had confirmed partial responses (ORR = 6.5%; 95%CI, 0.8-21.4%). Median DoR was 4.7 months (95% CI, 4.0-5.4 months), median PFS was 1.4 months (95% CI, 1.2-3.0 months) and median OS was 7.4 months (95% CI, 3.4-16.2 months). Lurbinectedin showed an acceptable, predictable and manageable safety profile. The most common grade 3/4 toxicity was neutropenia (40.6%; grade 4, 12.4%; febrile neutropenia, 3.1%). CONCLUSIONS: Considering the exploratory aim of this trial that evaluated a heterogeneous population of NETs patients, and the signs of antitumour activity observed (two confirmed partial responses and seven long disease stabilisations), further development of lurbinectedin is warranted in a more selected NETs population. TRIAL REGISTRATION NUMBER: Sponsor Study Code: PM1183-B-005-14. EudraCT number: 2014-003773-42. CLINICALTRIALS: gov reference: NCT02454972.","is_dataset_classified":null,"base_score":2.995732273553991,"endowment":2.995732273553991,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35830841","pmcid":null,"openalex_id":"https://openalex.org/W4284988128","authors":[],"funders":[],"total_grants":0,"fwci":2.7871,"citation_percentile":0.91303796,"influential_citations":0,"citation_trend":[{"year":2023,"count":11},{"year":2024,"count":4},{"year":2025,"count":4}],"oa_status":"hybrid","license":"cc-by-nc","oa_locations":[{"url":"http://www.ejcancer.com/article/S0959804922003756/pdf","host_type":"journal"},{"url":"http://www.ejcancer.com/article/S0959804922003756/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804922003756?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0959804922003756?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ejca.2022.06.024","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35830841","host_type":"repository"}],"fields_of_study":["Neuroendocrine Tumor Research Advances","Lung Cancer Research Studies","Thyroid Cancer Diagnosis and Treatment","Carbolines","Heterocyclic Compounds, 4 or More Rings","Humans","Neuroendocrine Tumors","Response Evaluation Criteria in Solid Tumors"],"mesh_terms":["Carbolines","Heterocyclic Compounds, 4 or More Rings","Humans","Neuroendocrine Tumors","Response Evaluation Criteria in Solid Tumors"],"keywords":["Neutropenia","Medicine","Clinical endpoint","Internal medicine","Febrile neutropenia","Population","Phases of clinical research","Surrogate endpoint","Neuroendocrine tumors","Response Evaluation Criteria in Solid Tumors","Clinical trial","Oncology","Toxicity","Surgery","Small cell","Neuroendocrine Tumours","Phase Ii Trial","Lurbinectedin"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"eudract"},{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-28T15:25:33.188776Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}